Table 3.
Median values of the highest quality studies in vaginal disease annual rate parameters
| Parameter | Median value (low, high)a | Reference |
|---|---|---|
| Cure rate for both treated and untreated VAIN 1 | 0.1915 (0.1202, 0.2761) | Lin et al. [55] |
| Cure rate for both treated and untreated VAIN 2 | 0.1962 (0.0000, 0.3924) | Lin et al. [55] |
| Rate of distant vaginal cancer-associated death | 0.2983 (0.2342, 0.5529) | Huang et al. [56] |
| Rate of local vaginal cancer-associated death | 0.0729 (0.0456, 0.1531) | Huang et al. [56] |
| Rate of progression from CIS 2 to local vaginal cancer | 0.0184 (–) | Kim et al. [57] |
| Rate of progression from local to regional vaginal cancer | 0.1308 (–) | Frank et al. [58] |
| Rate of progression from regional to distant vaginal cancer | 0.0657 (0.0325, 0.0989) | Frank et al. [58] |
| Rate of progression from VAIN 1 to VAIN 2/3 | 0.0317 (0.0106, 0.0795) | Kim et al. [57] |
| Rate of regional vaginal cancer-associated death | 0.1174 (0.1093, 0.2032) | Huang et al. [56] |
| Rate of regression from VAIN 1 to recovered or persistent HPV | 4.1099 (3.0809, 6.1821) | Ao et al. [59] |
| Rate of regression from VAIN 2/3 to recovered or persistent HPV | 3.4012 (3.2012, 4.2204) | Ao et al. [59] |
CIS carcinoma in situ, HPV human papillomavirus, VAIN vaginal intraepithelial neoplasia
aRates are in units of 1/years. For parameters with only one value reported in their high-quality study, the ranges were represented as “(–)”